Proto Labs Inc: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 5, 2023 and accepted by EDGAR at May 5, 2023, 16:41 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $125.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $72.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-01-01 to 2023-03-31 | $53.8m | us-gaap:GrossProfit |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $10.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | $3.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $2.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | $2.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | $0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 26,605,787 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | $22.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $3.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2023-01-01 to 2023-03-31 | $21.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-03-31 | $62.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $188.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $791.4m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $78.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $108.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $683.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-23-012837. Last ingested by Listed: Oct 29, 2026, 14:32 ET. Listed shows no prices and gives no investment advice.